Seagen

Seagen was founded in 1997 as Seattle Genetics on a specific therapeutic bet: that the antibody-drug conjugate — a targeted monoclonal antibody chemically linked to a cytotoxic payload, designed to deliver the payload to a tumour cell rather than to the whole patient — could be developed into a workable therapeutic class rather than remain the perpetually-promising research idea it had been through the previous two decades. The company changed its name from Seattle Genetics to Seagen in 2020, having by that point become the American reference firm in the ADC class, with Adcetris on the market for Hodgkin lymphoma and a pipeline that would produce three further approved ADCs over the next several years. Pfizer agreed to acquire the company for approximately $43 billion in March 2023 and closed the acquisition in December of the same year; the Bothell, Washington operations continue as a Pfizer oncology business unit.

Seagen designed, manufactured, and commercialised antibody-drug conjugates and related targeted-oncology therapies. Its four FDA-approved products at the time of the Pfizer close were Adcetris (brentuximab vedotin) for CD30-expressing lymphomas, Padcev (enfortumab vedotin) for advanced urothelial cancer, Tukysa (tucatinib) for HER2-positive metastatic breast cancer (this one a small-molecule kinase inhibitor rather than an ADC), and Tivdak (tisotumab vedotin) for cervical cancer. The ADC platform work — auristatin-based linkers, tumour-targeting antibody engineering, and the manufacturing chemistry that lets an ADC be produced at commercial scale — was the deep technological asset that made the firm the acquisition target Pfizer pursued.

Two things distinguish Seagen in the history of American oncology biotechnology: the persistence of the ADC bet, and the productivity of the platform once it was clinically established. Antibody-drug conjugates were treated in the 1990s as a technology whose commercial promise had not been matched by clinical results; Seagen kept working on them for a decade before Adcetris received its first FDA approval in 2011, and then produced three further approved ADCs over the following twelve years. The Pfizer acquisition was one of the largest in the history of the American biotechnology sector — evidence, in the acquirer’s own valuation, of what a durable platform bet in oncology therapeutics can be worth once the underlying technology is finally delivering.